TCP-25 is under clinical development by In2cure and currently in Phase I for Epidermolysis Bullosa. According to GlobalData, Phase I drugs for Epidermolysis Bullosa have a 96% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how TCP-25’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TCP-25 overview
TCP-25 is under development for the treatment of inflammation and infections during surgery, wound healing, acute respiratory distress syndrome, non-healing leg ulcers, dystrophic epidermolysis bullosa and eye infections. The drug candidate is administered through topical route. The therapeutic candidate is a thrombin derived anti-endotoxic host defense recombinant peptide.
In2cure overview
In2cure is a biotechnology company engaged in research and development of peptide based drugs for the treatment of infectious and inflammatory diseases. The company is headquartered in Lund, Vastra Gotaland, Sweden.
For a complete picture of TCP-25’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
